Clinical trials: Cell Transplantation
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)
The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the severe combined immunodeficiency (SCID) caused by mutations in the human DCLRE1C gene (Artemis) by transplantation of a single dose of…
- Trial name
- ARTEGENE (NCT05071222)
- Testing
- ARTEGENE drug product
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma, Disorder Related to Bone Marrow Transplantation
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated…
- Trial name
- NCT00506129
- Testing
- Fludarabine, Melphalan, Allogeneic Transplant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
In the transplant community, there is debate regarding the most appropriate food services for stem cell transplant patients. Recommendations regarding the use of low bacterial diets have been based on theoretical concepts of…
- Trial name
- NCT01687231
- Testing
- Non-neutropenic Diet
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Background: Allogeneic blood or marrow transplant is when stem cells are taken from one person s blood or bone marrow and given to another person. Researchers think this may help people with immune system problems.
- Conditions
- Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases, Autoimmune Lymphoproliferative
- Trial name
- NCT02579967
- Testing
- Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L
- Where
- 2 sites in United States
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
CML, AML
Umbilical Cord Blood Transplant for Hematological Malignancies
This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant.
- Conditions
- CML, AML, MDS, ALL
- Trial name
- UCB (NCT00891592)
- Testing
- Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Malignant Diseases, Non-malignant Diseases
CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function
The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor.
- Trial name
- NCT02162511
- Testing
- CliniMACS CD34+ cell enrichment and T-cell depletion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rajni Agarwal
Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)
Primary Objective: The primary objective of this study is to assess the tolerability and safety of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic, Stem Cell Transplant Complications
- Trial name
- BOSTON-4 (NCT04107675)
- Testing
- Liposomal Cyclosporine A
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Zambon SpA
Relapsed Leukemia, Refractory Leukemia
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
This is a Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of chemotherapy combining with HLA-mismatched G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion as a…
- Trial name
- NCT07297173
- Testing
- Chemotherapy, HLA-mismatched GPBMC infusion, Allogeneic Stem Cell Transplantation
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Beijing 302 Hospital
Acute Myeloid Leukemia in Remission, Primary Myelofibrosis
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with tacrolimus and sirolimus in preventing acute graft-versus-host disease during reduced intensity donor hematopoietic cell…
- Conditions
- Acute Myeloid Leukemia in Remission, Primary Myelofibrosis, Primary Myelofibrosis, Prefibrotic Stage, Secondary Acute Myeloid Leukemia
- Trial name
- NCT02528877
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate
- Where
- United States
- Sponsor
- City of Hope Medical Center
Systemic Lupus Erythematosus
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus
This study is to evaluate the safety and efficacy of human umbilical cord derived mesenchymal stem cells transplantation in systemic lupus erythematosus.
- Trial name
- NCT03219801
- Testing
- mesenchymal stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hebei Medical University
Malignant Solid Tumour, Hematologic Malignancies
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
The primary objective of this study is to assess the feasibility of a multi-institutional study that collects cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or…
- Conditions
- Malignant Solid Tumour, Hematologic Malignancies, Planned Hematopoietic Cell Transplantation
- Trial name
- NCT02786628
- Testing
- Physical performance testing and patient-generated health data
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Scleroderma, Systemic, Sclerosis
Scleroderma: Cyclophosphamide or Transplantation
SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation.
- Conditions
- Scleroderma, Systemic, Sclerosis, Autoimmune Disease
- Trial name
- SCOT (NCT00114530)
- Testing
- mHSCT, cyclophosphamide
- Where
- 17 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
According to international guidelines, upfront therapy for transplant eligible myeloma patients should include triplet induction containing proteasome inhibitor and immunomodulatory agent, autologous stem cell transplant, PI+Imid…
- Trial name
- IFM 2018-04 (NCT03606577)
- Testing
- Carfilzomib, Daratumumab, Lenalidomide
- Where
- 12 sites in France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
Hematologic Diseases
Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation
Aim of this study will evaluate the Impact of Covid-19 vaccine on Safety and Efficacy of Hematological Patients Received Allogeneic Hematopoietic Stem Cell Transplantation.
- Trial name
- NCT05587881
- Testing
- COVID-19 vaccine(donor), COVID-19 vaccine(patient)
- Where
- China
- Sponsor
- The First Affiliated Hospital of Soochow University
Autologous Hematopoietic Stem Cell Transplantation, Conditioning
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma
- Trial name
- NCT03385096
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diffuse Large B Cell Lymphoma, Large-cell Lymphoma
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
Phase 1 study to assess the safety, preliminary efficacy of CD19 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with diffuse large B-cell lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma, B-Cell, Lymphoma
- Trial name
- NCT04052061
- Testing
- CD19 t-haNK
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Melanoma, Myelodysplastic Syndrome
SCRI Tissue Testing Registry
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients…
- Conditions
- Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Trial name
- NCT00965861
- Testing
- Tissue Registry Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Spinal Cord Injuries
Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury
This study aim to evaluate the safety and efficacy of intrathecal transplantation of allogeneic umbilical cord derived mesenchymal stem cells (UC-MSC) for treatment of different phrases of spinal cord injury.
- Trial name
- NCT03521323
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Acute Graft Versus Host Disease
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
This research trial is designed to study the safety and effectiveness of combining the study drug, Natalizumab (Tysabri®) with the standard treatment, the use of steroids, as a new treatment for acute graft versus host disease…
- Trial name
- NCT02133924
- Testing
- natalizumab, steroids
- Where
- 12 sites in United States
- Volunteers
- 76 people
- Sponsor
- John Levine
Respiratory Syncytial Virus Infections
Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients
This study tests the effects of an experimental drug PC786 in people infected with Respiratory Syncytial Virus (RSV). PC786 may be useful in treating patients infected with RSV as it works by interfering with the way the virus…
- Trial name
- TreatRSV1 (NCT03715023)
- Testing
- PC786, SOC
- Where
- 7 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Pulmocide Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.